The Food and Drug Administration on Friday expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.
Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA expanded the approval of GSK's respiratory ...
Moderna’s messenger RNA vaccine for respiratory syncytial virus (RSV) is now FDA approved, a regulatory decision that comes nearly a year after GSK and Pfizer won regulatory approvals for their ...
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
Moderna’s shot is the third RSV vaccine for people 60 and older that’s gotten the green light from the FDA and the first mRNA vaccine among them. It’s the company’s second product to ...
The first respiratory syncytial virus (RSV) vaccine has been approved for adults aged 50 to 59 years who are at increased ...
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes 1 Clinical development program continues to evaluate safety and immunogenicity in ...